Value
4.3/10data confidence 50%| Component | Sub-score |
|---|---|
| P/S | 9.3 |
| EV/EBITDA | 0.0 |
| Analyst target | 4.0 |
DHC · Why this verdict
Why Diversified Healthcare Trust (DHC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score3.7/10
ConfidenceHIGH
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue has declined approximately 5% year-over-year, indicating that the asset base is shrinking faster than any potential pricing or occupancy improvement can offset. Growth breakdown | Revenue growth turns positive above 0% year-over-year for 2 consecutive quarters. | →Stable |
| CounterManaged asset dispositions can temporarily depress reported revenue even as the quality and coverage of the remaining portfolio improves; a declining top line may reflect deliberate portfolio pruning rather than underlying demand weakness. | ||
The company scores 2 out of 9 on the Piotroski financial-strength framework—among the weakest possible readings—with no identifiable competitive moat, signaling that the underlying business lacks the financial health to self-fund a recovery. Quality breakdown | Piotroski F-Score improves to at least 5 out of 9 over the next four quarters. | →Stable |
| CounterHealthcare REITs with distressed balance sheets can recover sharply when occupancy rates inflect; a catalyst such as a refinancing transaction or asset sale could rapidly improve the financial-strength profile without requiring organic improvement. | ||
The company has beaten consensus estimates in each of the last four quarters with an average positive surprise of nearly 24%, but every actual result was a loss—ranging from -$0.06 to -$0.22 per share—meaning the streak reflects smaller losses than feared, not progress toward breakeven. Earnings | Reported EPS turns positive above $0.00 for at least 2 consecutive quarters. | →Stable |
| CounterLosses that are consistently smaller than expected suggest management has credible visibility into cost control; a sustained pattern of narrowing losses can represent a legitimate path toward breakeven and eventual profitability. | ||
The stock has already run past the analyst consensus target, implying roughly 9.8% downside to that target from the current price, while momentum sits at the minimum acceptable threshold and the risk/reward geometry is unfavorable. Bear case | Analyst consensus price target rises above the current price of $8.83, establishing positive headroom to target. | →Stable |
| CounterAnalyst targets for distressed REITs are often anchored to net asset value estimates that may underweight option value from a potential restructuring or strategic transaction. | ||
Revenue has declined approximately 5% year-over-year, indicating that the asset base is shrinking faster than any potential pricing or occupancy improvement can offset.
→StableGrowth breakdown
- Expectation
- Revenue growth turns positive above 0% year-over-year for 2 consecutive quarters.
CounterManaged asset dispositions can temporarily depress reported revenue even as the quality and coverage of the remaining portfolio improves; a declining top line may reflect deliberate portfolio pruning rather than underlying demand weakness.
The company scores 2 out of 9 on the Piotroski financial-strength framework—among the weakest possible readings—with no identifiable competitive moat, signaling that the underlying business lacks the financial health to self-fund a recovery.
→StableQuality breakdown
- Expectation
- Piotroski F-Score improves to at least 5 out of 9 over the next four quarters.
CounterHealthcare REITs with distressed balance sheets can recover sharply when occupancy rates inflect; a catalyst such as a refinancing transaction or asset sale could rapidly improve the financial-strength profile without requiring organic improvement.
The company has beaten consensus estimates in each of the last four quarters with an average positive surprise of nearly 24%, but every actual result was a loss—ranging from -$0.06 to -$0.22 per share—meaning the streak reflects smaller losses than feared, not progress toward breakeven.
→StableEarnings
- Expectation
- Reported EPS turns positive above $0.00 for at least 2 consecutive quarters.
CounterLosses that are consistently smaller than expected suggest management has credible visibility into cost control; a sustained pattern of narrowing losses can represent a legitimate path toward breakeven and eventual profitability.
The stock has already run past the analyst consensus target, implying roughly 9.8% downside to that target from the current price, while momentum sits at the minimum acceptable threshold and the risk/reward geometry is unfavorable.
→StableBear case
- Expectation
- Analyst consensus price target rises above the current price of $8.83, establishing positive headroom to target.
CounterAnalyst targets for distressed REITs are often anchored to net asset value estimates that may underweight option value from a potential restructuring or strategic transaction.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Diversified Healthcare Trust carries business quality that falls well below the minimum threshold for a sustainable investment, with a Piotroski financial-strength score of just 2 out of 9, no identifiable competitive moat, and revenue declining roughly 5% year-over-year; while management has beaten deeply negative EPS estimates in each of the last four quarters, every actual result was a per-share loss, meaning the beat streak reflects losses that are slightly less severe than feared rather than any meaningful progress toward profitability.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.6 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
1.2/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 1.2 |
- ▸Declining revenue: -5%
Momentum
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.4 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 6.2 |
| erm sentiment | 5.0 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.4 |
| quality rank | 0.0 |
| growth rank | 1.3 |
Technical
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.3 |
| support resistance | 3.4 |
| 52w position | 8.9 |
Risk (lower is worse)
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.7 |
| days to cover | 5.3 |
| volatility | 2.6 |
| put call | 6.7 |
| implied vol | 2.2 |
| beta | 2.4 |
| debt equity | 4.0 |
- ▸High IV: 67%
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 5.2 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 43.0%
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:28d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.8<4.5
- ASYMMETRY:-0.7=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.72
Upside
-8.1%
Downside
11.3%
Sizing output
AVOID
SetupRange Bound — RSI 58 mid-range, Bollinger mid-band
EdgeCatalyst-Driven — Earnings in 28d with 4/4 beat streak
SuitabilityAggressive — Beta 2.27>1.3, MCap $2.2B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Catalyst at 7.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.8<4.5.
The strongest dimensions are Catalyst at 7.0, Technical at 5.5, and Sentiment at 5.4; the weakest are Growth at 1.2, Quality at 1.3, and Momentum at 3.8. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of -0.72 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Critically Weak Business Quality
Trip ifPiotroski F-Score improves to 5 or above for 2 consecutive reporting periods.
- P2Declining Revenue Trajectory
Trip ifRevenue growth turns positive above 0% year-over-year for 2 consecutive quarters.
- P3Beats On Negative Eps Base
Trip ifReported EPS turns positive above $0.00 for 2 consecutive quarters.
- P4Price Above Analyst Consensus
Trip ifAnalyst consensus price target rises above $9.50.